Healthpeak Properties has logged a mixed share price record, with a strong 3 year return but weaker stretches over shorter and longer windows, which naturally puts attention on what investors are paying for its future cash flows. With the stock recently closing at US$19.02, the key issue is how that price stacks up against the cash the real estate investment trust can realistically generate over time.
For investors, the debate is whether Healthpeak Properties' current share price is adequately supported by the cash flows implied by a Discounted Cash Flow (DCF) view.
If you want to pressure test whether Healthpeak Properties' cash flow debate applies elsewhere, compare it with a wider group of stocks screened for 29 high quality undervalued stocks
The Discounted Cash Flow (DCF) model here is built on Healthpeak Properties' adjusted funds from operations. On this view, the trust is generating last twelve month free cash flow of about $1.29b, with the forecast path assuming that cash generation continues to grow rather than shrink. That profile suits a REIT like Healthpeak Properties, where the focus is on recurring rental income feeding into steady adjusted cash flows.
Analyst and model estimates point to free cash flow in the coming years remaining in the same ballpark, with gradual expansion rather than sharp swings, which fits a more mature portfolio of properties. When those projected $ cash flows are discounted back and stacked up against the current share price of $19.02, the DCF view suggests the estimated intrinsic value for Healthpeak Properties sits substantially above where the stock is trading today. Find out what Healthpeak Properties could be worth using our Discounted Cash Flow (DCF) estimate.
Simply Wall St Narratives for Healthpeak Properties pick up where the valuation puzzle leaves off and explain which paths for growth, profitability and future earnings would need to hold for the stock to be worth materially more or less than today. Narratives are on the Community page and turn a single DCF or valuation ratio into a set of explicit future conditions so you can monitor whether Healthpeak Properties' actual progress lines up with the scenario that the price implies.
Bulls see Healthpeak Properties as mispriced cash flow leverage, while bears think lab softness and refinancing risk already cap what you can reasonably expect.
Bull case: 16% undervalued
"The current valuation implies that Healthpeak Properties' share price does not fully reflect the implied FFO yield above 10% on recent buybacks..."
Discover why this Narrative puts Healthpeak Properties at 16% undervalued.
Bear case: 11% overvalued
"Bearish analysts expect Healthpeak Properties to face ongoing volatility in occupancy and earnings as tenant risk, market concentration, and life science leasing costs keep medium term growth muted..."
Explore why this Narrative puts Healthpeak Properties at 11% overvalued.
Price and cash flow only tell part of the story, because the people making the capital decisions, signing off on deals and setting incentives can heavily influence where Healthpeak Properties goes next. See who runs Healthpeak Properties and how they are paid.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com